Emerging gene and cell therapies hold promise for glaucoma – a disease that slowly destroys the retinal ganglion cells (RGCs) (the nerve cells sending vision signals to the brain) and impedes the eye’s natural drainage of fluid (the aqueous outflow pathways). These next-generation treatments aim either to protect or regenerate RGCs (neuroprotection) or to improve outflow tissue function and lower intraocular pressure. In April 2026 several first-in-human trials will begin for such approaches. Below we summarize their main features – vectors, molecular targets, dosing plans and immune safety measures – as well as how they are delivered and controlled. We also note the ethical issues of sham controls and the required long-term safety monitoring.

Gene Therapy for RGC Neuroprotection

Some trials deliver genes encoding neuroprotective factors into the eye to help RGCs survive. For example, one approach uses a harmless viral vector (often an adeno-associated virus, AAV) to carry the gene for ciliary neurotrophic factor (CNTF) or brain-derived neurotrophic factor (BDNF) into retinal cells. These proteins act like growth factors to keep RGCs healthy. (Indeed, laboratory studies report that factors such as BDNF and glial cell–derived neurotrophic factor (GDNF) can greatly improve RGC survival ().) In an upcoming Phase 1 trial, for instance, patients will receive an intravitreal (into the gel of the eye) injection of an AAV vector carrying the human CNTF gene. The trial is dose-escalating: each group of patients will get a higher viral dose to find the safe and active range (typical Phase 1 design). Blood and eye exams will regularly check for immune reactions – for example, measuring if the body makes antibodies (binding or neutralizing) against the viral capsid or the new gene product (). Many ocular gene trials also use short courses of corticosteroid eye drops around the time of injection to blunt inflammation () ().

Another putative gene therapy targets the neuronal degeneration process itself. For instance, trials may deliver genetic “braking” tools (like short hairpin RNA or CRISPR nucleases) to suppress harmful signals in RGCs. One example in animal studies used an AAV-delivered Cas9 gene-editing system to knock out the Wallerian degeneration pathway (which causes axons to die after injury). In mice, such treatments kept RGC axons more intact. Key points: gene therapies for RGCs typically use intravitreal or subretinal injections (small-eye surgery akin to injections for macular degeneration ()) and monitor vision function by elective tests (imaging, visual field, etc.) over time. Because gene expression is long-lasting, trials plan extended follow-up. FDA guidance, for example, calls for up to 15 years of post-treatment monitoring in gene therapy trials, focusing on late adverse events like tumor development (). A registry of treated patients may also be kept to flag any rare issues.

Gene Therapy for Aqueous Outflow / IOP Lowering

Other April 2026 trials aim at lowering eye pressure by improving the drainage of fluid. These target the trabecular meshwork and Schlemm’s canal (the tissues in the iridocorneal angle that normally let aqueous fluid exit the eye)

Support the show